@lagosgirliesroom's weight-loss injection claims, fact-checked
Quick answer
The video promotes what appears to be compounded tirzepatide, a dual GIP/GLP-1 receptor agonist, through a Nigerian telehealth service called Dokitami. The creator cites weight loss of 7, 10 kg in 30 days, a figure not supported as a mean outcome in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), which reported approximately 20.9% body weight reduction over 72 weeks. No information is provided about clinical screening, dosing protocols, or monitoring, which are required for safe use of injectable peptide therapies.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @lagosgirliesroom actually say?
The creator claims she is revealing where Lagos women are secretly getting "weight loss injections" that cause people to drop "7 to 10 kg in 30 days without killing themselves in the gym or starving." She identifies the product as "the same compound" as tirzepatide, available in Nigeria through a service called Dokitami, supervised by a verified doctor.
She also frames the weight loss as a financial strategy: "You can't be looking out of shape or obese and expect to see a man who has spent the company on you invest in looking good to get return on investment." That framing is worth naming directly because it ties body composition to relationship worth, which is a separate problem from the medical claims, but it shapes why someone might skip the safety questions entirely.
The pitch ends with urgency: "Don't dawl. If you've been waiting for a sign, this is it." That is a classic direct-response sales technique, not a medical consultation.
Does the science back this up?
Tirzepatide is a real drug with strong clinical evidence. The claim that it produces rapid weight loss is not invented. But the specific numbers and timeline deserve scrutiny, and the "no diet, no exercise" framing misrepresents what the trials actually showed.
The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed participants on the highest dose of tirzepatide lost an average of 20.9% of body weight over 72 weeks. That is roughly 18 months. The dramatic early losses seen in some individuals, sometimes 3, 5 kg in the first four weeks, are partly water weight and glycogen depletion, not pure fat loss. Losing 7, 10 kg of actual fat in 30 days on any GLP-1 or GIP/GLP-1 agonist is not a typical or expected outcome. It is not impossible in a heavier individual with fluid changes, but advertising it as a standard result is misleading.
The SURMOUNT trials also included lifestyle counseling. Participants were not eating freely. Presenting tirzepatide as a replacement for dietary change contradicts the study conditions that produced those results.
What did they get wrong (or right)?
Credit where it is due: tirzepatide does work as a weight management agent, and the existence of compounded versions in markets outside the US and EU is a real phenomenon. Calling it "the same compound" as a branded product is where things go wrong legally and clinically. Compounded tirzepatide is not the same as Zepbound or Mounjaro in terms of regulatory approval, manufacturing standards, or verified bioequivalence. The FDA has been explicit about this distinction.
The "7 to 10 kg in 30 days" claim lacks a cited source. No peer-reviewed trial reports that as an average outcome at four weeks. It may reflect outlier anecdotes or marketing copy.
The framing of "no crash diets" is also inaccurate. GLP-1 and GIP agonists work partly by reducing appetite and slowing gastric emptying, which means users naturally eat less. Calling that "no dieting" is technically misleading: the drug produces the caloric deficit that a diet would otherwise require. Users still need adequate protein and nutritional guidance to avoid muscle loss, as shown in Wilding et al., 2021, NEJM, where lean mass loss was a documented concern.
What should you actually know?
Tirzepatide is a legitimate, evidence-backed medication. If you are considering it, the access pathway matters as much as the molecule. The creator mentions a "real MDC and verified doctor" but provides no details about what that supervision involves, how dosing is determined, or what monitoring is required.
GLP-1 and GIP agonists carry real side effects including nausea, vomiting, pancreatitis risk, and potential thyroid concerns flagged in animal studies (though not confirmed in humans at therapeutic doses per the SURMOUNT safety data). Starting without baseline bloodwork or a proper medical history review is a risk, not a shortcut.
Compounded peptides also vary in quality. Without knowing the source, concentration, and sterility standards of what Dokitami is dispensing, there is no way to verify the product matches what it claims to be. That is not a reason to dismiss compounding categorically, but it is a reason to ask harder questions before injecting anything.
If you are in Nigeria and genuinely interested in GLP-1 therapy, seek a consultation with a licensed physician who can review your metabolic health, contraindications, and goals before any prescription is written.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @lagosgirliesroom's weight-loss injection claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
@lagosgirliesroom's weight-loss injection claims, fact-checked is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
The video promotes what appears to be compounded tirzepatide, a dual GIP/GLP-1 receptor agonist, through a Nigerian telehealth service called Dokitami.
FormBlends verdict
The video promotes what appears to be compounded tirzepatide, a dual GIP/GLP-1 receptor agonist, through a Nigerian telehealth service called Dokitami. The creator cites weight loss of 7, 10 kg in 30 days, a figure not supported as a mean outcome in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), which reported approximately 20.9% body weight reduction over 72 weeks. No information is provided about clinical screening, dosing protocols, or monitoring, which are required for safe use of injectable peptide therapies.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video promotes what appears to be compounded tirzepatide, a dual GIP/GLP-1 receptor agonist, through a Nigerian telehealth service called Dokitami. The creator cites weight loss of 7, 10 kg in 30 days, a figure not supported as a mean outcome in the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), which reported approximately 20.9% body weight reduction over 72 weeks. No information is provided about clinical screening, dosing protocols, or monitoring, which are required for safe use of injectable peptide therapies.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed mean weight loss of 20.9% on tirzepatide, but over 72 weeks, not 30 days.
- Early rapid weight loss on GLP-1/GIP agonists partly reflects water and glycogen loss, not equivalent fat reduction.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed mean weight loss of 20.9% on tirzepatide, but over 72 weeks, not 30 days.
- Early rapid weight loss on GLP-1/GIP agonists partly reflects water and glycogen loss, not equivalent fat reduction.
- Compounded tirzepatide is not regulatory-equivalent to Zepbound or Mounjaro; the FDA has stated this explicitly and repeatedly.
- GLP-1 and GIP agonists reduce appetite as their core mechanism, meaning users are still in a caloric deficit, just drug-induced rather than willpower-induced.
- Lean mass loss is a documented risk with rapid weight loss on semaglutide and tirzepatide without adequate protein intake (Wilding et al., 2021, NEJM).
- Safe use of injectable peptide therapies requires baseline medical screening, contraindication review, and ongoing monitoring, none of which are mentioned in this video.
- Urgency-based sales language such as 'Don't dawl, send a message now' is a marketing technique, not a medical recommendation.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Lagos Girlies Room 💅💕🤩 · TikTok creator
32.0K views on this video
GET YOUR WEIGHT-LOSS INJECTION FROM @Dokitami #weightloss
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Lagos Girlies Room 💅💕🤩, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.